LAS VEGAS – April 29, 2020 – The growth of NSCLC Market is expected to increase due to increasing incident cases of NSCLC, continuous uptake of approved therapies mainly immune checkpoint inhibitors, increasing use of biomarker testing, probable entry of potential premium price emerging therapies and increasing awareness of mutations, among others.
DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on “Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030” to its portfolio.
Key Highlights from report are:
Request for free sample pages to know more on Non-Small Cell Lung Cancer Market Forecast
NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers. The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.
The total NSCLC incident cases in the 7MM were observed to be 484,726 cases in 2017.
Click here to know more on Non-Small Cell Lung Cancer pipeline
NSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.
Drugs covered in the report are:-
There are several key players robustly involved in developing potential products such as
Key Players covered in the report are:-
And many others
The report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.
Market Driver
Market Barrier
The reasons for buying this report:
1.
Key Insights
2.
Executive Summary of NSCLC
3.
SWOT Analysis of NSCLC
4.
Non-Small Cell Lung Cancer Market Overview at a Glance
5.
NSCLC Disease Background and Overview
6.
NSCLC Diagnosis
7.
Non-Small Cell Lung Cancer Epidemiology and Patient Population
7.1.
The United States Epidemiology
8.
EU-5 Epidemiology
8.1.
Germany
8.2.
France
8.3.
Italy
8.4.
Spain
8.5.
The United Kingdom
9.
Japan Epidemiology
10.
Non-Small Cell Lung Cancer Current Treatment Practices
11.
Guideline of NSCLC
12.
Unmet Needs of NSCLC
13.
Key Endpoints in NSCLC Clinical Trials
14.
Non-Small Cell Lung Cancer Marketed Therapies
14.1.
Key Cross
14.2.
Rozlytrek (Entrectinib): Hoffmann-La Roche (Genentech)
14.3.
Imfinzi (Durvalumab): AstraZeneca
14.4.
Opdivo (Nivolumab): Bristol-Myers Squibb
14.5.
Tecentriq (Atezolizumab): Genentech/Hoffmann-La Roche
14.6.
Keytruda (Pembrolizumab): Merck
14.7.
Tafinlar(Dabrafenib)in Combination with Mekinist(Trametinib): Novartis
14.8.
Tagrisso(Osimertinib): AstraZeneca
14.9.
Lorbrena/Lorviqua (Lorlatinib): Pfizer
14.10.
Vizimpro(Dacomitinib): Pfizer
14.11.
Alunbrig (Brigatinib): Takeda Pharmaceuticals
14.12.
Alecensa (Alectinib): Hoffmann-La Roche
14.13.
Vitrakvi (Larotrectinib): Bayer Healthcare
14.14.
Portrazza (Necitumumab): Eli Lilly
15.
Non-Small Cell Lung Cancer Emerging Therapies
15.1.
Nazartinib (EGF816): Novartis Pharmaceuticals
15.2.
Capmatinib (INC280): Novartis Pharmaceuticals
15.3.
Tepmetko (tepotinib): Merck KGaA
15.4.
Merestinib: Eli Lilly and Company
15.5.
JNJ-61186372 (JNJ-6372): Janssen Research & Development
15.6.
Lazertinib: Yuhan Corporation/ Janssen Research & Development
15.7.
Vemurafenib Plus Cobimetinib: Hoffmann-La Roche
15.8.
X-396 (Ensartinib): Xcovery
15.9.
Plinabulin: BeyondSpring Pharmaceuticals
15.10.
Tedopi (OSE2101): OSE Immunotherapeutics
15.11.
Selpercatinib (LY3527723/ LOXO-292): Eli Lilly and Company
15.12.
SAR408701: Sanofi
15.13.
Braftovi (encorafinib) + Mektovi (binimetinib): Pfizer
15.14.
PADCEV (enfortumab vedotin/ASG-22ME): Astellas Pharma/Seattle Genetics
15.15.
Pralsetinib (BLU-667): Blueprint Medicines Corporation
15.16.
TAK-788: Takeda
15.17.
Canakinumab (ACZ885): Novartis Pharmaceuticals
15.18.
Avelumab (Bavencio): Merck KGaA and Pfizer
15.19.
Veliparib (ABT-888): AbbVie
15.20.
Sitravatinib (MGCD516): Mirati Therapeutics/Bristol-Myers Squibb/Beigene
15.21.
Tesevatinib: Kadmon Corporation
15.22.
Romiplostim: Amgen
15.23.
Cabozantinib: Exelixis/Ipsen/Takeda
15.24.
Sym015: Symphogen
15.25.
AMG 510: Amgen
15.26.
INCMGA00012 (MGA012): Incyte Corporation/ Zai Lab Limited
15.27.
Libtayo (Cemiplimab): Regeneron Pharmaceuticals
15.28.
Bavituximab: Peregrine Pharmaceuticals/ Avid Bioservices, Inc
15.29.
M7824 (Bintrafusp alfa): GlaxoSmithKline/Merck KGaA
16.
NSCLC Seven Major Market Analysis
17.
PD-L1—Market Size
18.
BRAF Mutation—Market Size
19.
c-MET Mutation—Market Size
20.
EGFR Mutation—Market Size
21.
ALK-Mutation—Market Size
22.
Market Access and Reimbursement of NSCLC Therapies
23.
Market Drivers of NSCLC
24.
Market Barriers of NSCLC
25.
Appendix
26.
DelveInsight Capabilities
27.
Disclaimer
28.
About DelveInsight
Request a Webex Demo to get a walk-through of the report: https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-market
DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/